Medical Condition News

RSS

FDA clears CooperVision's Avaira Toric contact lenses for astigmatism

CooperVision, Inc. today announced that the U.S. Food and Drug Administration has granted a Special 510(k) clearance for CooperVision's Avaira Toric two-week silicone hydrogel contact lenses for astigmatism.

6 Apr 2012

Collaborative Cross project to develop lab mice with increased genetic diversity

With a 95 percent genomic similarity to humans, mice have long been used to learn about the genetic causes of human disease. Once researchers can shine a light on the genetic factors that cause disease in mice, they can start to develop prevention and treatment options to protect the human population.

6 Apr 2012

Astellas' mirabegron for OAB receives FDA advisory committee approval

Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the Reproductive Health Drugs Advisory Committee of the U.S. Food and Drug Administration voted that the overall risk/benefit assessment supports approval of mirabegron for the treatment of overactive bladder.

6 Apr 2012

Spectrum’s apaziquone Phase 3 trials on bladder cancer do not meet primary endpoint

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the two double blind, randomized, placebo controlled, Phase 3 clinical trials for apaziquone did not meet their primary endpoint of a statistically significant difference in the rate of tumor recurrence at 2 years between the two arms.

6 Apr 2012

Evergreen Healthcare employs transanal endoscopic microsurgery for colorectal tumor removal

Evergreen Healthcare today announced that it has successfully integrated a colorectal procedure called transanal endoscopic microsurgery to its growing suite of minimally invasive surgical options, reducing the need for major surgery and providing patients with faster recovery times.

6 Apr 2012

Steps to reduce risk of social media sites among teenagers

While social media has made connecting and communicating with anyone at any time as easy as pie, it also has altered teen's social skills and behaviors. Sites such as Facebook, Twitter and MySpace have proven to be great tools to expedite the development of empathy, encourage task-switching or even bring somewhat shy individuals a little more out of their shells. However, social media sites have also fostered a host of psychological and behavioral problems.

6 Apr 2012

Towards a drug to control cystic fibrosis

Harvard stem cell researchers at Massachusetts General Hospital (MGH) have taken a critical step in making possible the discovery in the relatively near future of a drug to control cystic fibrosis (CF), a fatal lung disease that claims about 500 lives each year, with 1,000 new cases diagnosed annually.

6 Apr 2012

CHL's inflammation biomarkers to be showcased at TEDMED 2012 conference

Cleveland HeartLab Inc. (CHL), a rapidly growing specialty clinical laboratory and cardiovascular disease management company, today announced that its panel of inflammation biomarkers will be featured at next week's TEDMED 2012 conference in Washington.

6 Apr 2012

Key finding in regulation of intraocular pressure in glaucoma

A six-year collaboration between two faculty members of Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine has yielded new insight regarding the regulation of intraocular pressure (IOP) in glaucoma - an irreversible blinding disease that causes progressive visual impairment due to optic nerve damage and is the leading cause of blindness worldwide.

6 Apr 2012

Akebia completes AKB-6548 Phase 2 study for anemia in CKD patients

Akebia Therapeutics, Inc., a pharmaceutical discovery and development company focused on anemia and vascular disorders, today announced that it has successfully completed a randomized, double-blinded, placebo-controlled Phase 2 dose-ranging study of AKB-6548 in patients with stage 3 and 4 chronic kidney disease (CKD).

6 Apr 2012

Ameritox, Ridge Diagnostics partner to develop MDDScore test

Ridge Diagnostics, Inc., a neurodiagnostic company, announced today it has entered into an exclusive agreement with Ameritox, Ltd., a leader in medication monitoring, for the license rights to its proprietary developmental blood test MDDScore, a multiple biomarker analysis for Major Depressive Disorder (MDD) for primary care and pain physicians.

6 Apr 2012

Gold nanostars can deliver drug directly to cancer cell nucleus

Nanotechnology offers powerful new possibilities for targeted cancer therapies, but the design challenges are many. Northwestern University scientists now are the first to develop a simple but specialized nanoparticle that can deliver a drug directly to a cancer cell's nucleus -- an important feature for effective treatment.

6 Apr 2012

Cancer diagnosis associated with suicide, cardiovascular death

People who are diagnosed with cancer have a markedly increased risk of suicide and cardiovascular death during the period immediately after being given the diagnosis. This has been shown in a new study from Karolinska Institutet in Sweden, published in the prestigious scientific journal The New England Journal of Medicine.

6 Apr 2012

African-Americans and Hispanics with MDD less likely to get antidepressants

African-Americans and Hispanics with major depressive disorder are less likely to get antidepressants than Caucasian patients, and Medicare and Medicaid patients are less likely to get the newest generation of antidepressants.

6 Apr 2012

Advaxis, Karolinska Institutet enter collaboration to develop cat allergy vaccine

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has entered into a research collaboration with Professor Marianne van Hage, research group leader and Head of the Clinical Immunology and Allergy Unit and Vice Head of the Department of Medicine at Karolinska Institutet in Stockholm, Sweden.

6 Apr 2012

NEA Itching for a Cure 5K Walk to take place on April 28

The National Eczema Association (NEA) is proud to announce the FIRST ever walk for eczema: Itching for a Cure. The NEA Itching for a Cure 5K Walk will take place Saturday, April 28, 2012, in Asheville, North Carolina, on the University of North Carolina-Asheville campus.

6 Apr 2012

Delcath’s second generation CHEMOSAT system receives European CE Mark

Delcath Systems, Inc. today announced that the Company has received CE Mark approval for the second generation hemofiltration cartridge of the Company's proprietary Hepatic CHEMOSAT Delivery System.

6 Apr 2012

Doctors continue to prescribe dangerous nifedipine drug to elderly patients

Despite the fact that nifedipine increases the risk of heart attacks and death, doctors still prescribe this immediate-release blood pressure drug to elderly patients. The Cologne-based research group led by Ingrid Schubert has now published the results of their investigation in the current issue of Deutsches -rzteblatt International.

6 Apr 2012

USPTO issues patent to ChromaDex’s pterostilbene

The U.S. Patent and Trademark Office has granted patent #8,133,917 pertaining to the ingredient pterostilbene, which is licensed exclusively to ChromaDex Corp., an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, and marketer of BluScience, its new line of dietary supplements.

6 Apr 2012

FDA clears Devon Medical Products’ extriCARE 2400 NPWT system

Devon Medical Products, a global medical device designer, manufacturer, and distributor, today announced it has received Food & Drug Administration (FDA) 510(k) clearance to market its extriCARE 2400 Negative Pressure Wound Therapy (NPWT) system.

6 Apr 2012